CSPCY (CSPC Pharmaceutical Group) Other Stockholders Equity: $-301 Mil (As of Dec. 2025)


CSPCY CSPC Pharmaceutical Group Ltd CSPCY
74 GF Score
Price $4.19
GF Value $3.36
Valuation Modestly Overvalued
! 4 Warning Signs
View Full Analysis

What is CSPC Pharmaceutical Group Other Stockholders Equity?

CSPC Pharmaceutical Group CSPCY +9.11% 74 Other Stockholders Equity is $-301 Mil as of Dec. 2025. GuruFocus rates CSPCY with a GF Score™ of 74/100 and a GF Value™ of $3.36 (Modestly Overvalued). The stock has 4 warning signs investors should review.

CSPC Pharmaceutical Group's Other Stockholders Equity for the quarter that ended in Dec. 2025 was $-301 Mil.

CSPC Pharmaceutical Group's quarterly Other Stockholders Equity increased from Jun. 2025 ($-307 Mil) to Sep. 2025 ($0 Mil) but then declined from Sep. 2025 ($0 Mil) to Dec. 2025 ($-301 Mil).

CSPC Pharmaceutical Group's annual Other Stockholders Equity declined from Dec. 2023 ($-253 Mil) to Dec. 2024 ($-287 Mil) and declined from Dec. 2024 ($-287 Mil) to Dec. 2025 ($-301 Mil).

CSPC Pharmaceutical Group Other Stockholders Equity Historical Data

* Premium members only.

The historical data trend for CSPC Pharmaceutical Group's Other Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

CSPC Pharmaceutical Group Other Stockholders Equity Chart

CSPC Pharmaceutical Group Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Stockholders Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only -336.61 -279.79 -252.85 -286.92 -300.61

CSPC Pharmaceutical Group Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Other Stockholders Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 -306.76 0.00 -300.61 0.00
CSPCY
74GF Score
CSPC Pharmaceutical Group Ltd CSPCY
Other Stockholders Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

CSPC Pharmaceutical Group Other Stockholders Equity Calculation

Other Stockholders Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. GuruFocus lists following items in "Total Stockholders Equity" section:
Common Stock
Preferred Stock
Retained Earnings
Accumulated other comprehensive income (loss)
Additional Paid-In Capital
Treasury Stock
Other Stockholders Equity

What does a Other Stockholders Equity of $-301 Mil mean?
CSPC Pharmaceutical Group (CSPCY) has a Other Stockholders Equity of $-301 Mil as of Dec. 2025. Other Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. View historical data on CSPC Pharmaceutical Group and its competitors.
Is CSPC Pharmaceutical Group's Other Stockholders Equity too high?
CSPC Pharmaceutical Group's current Other Stockholders Equity is $-301 Mil. Overall, CSPC Pharmaceutical Group has a GF Score™ of 74/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does CSPC Pharmaceutical Group's Other Stockholders Equity compare to LLY and JNJ?
CSPC Pharmaceutical Group's Other Stockholders Equity of $-301 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Stockholders Equity for a Drug Manufacturers company?
A good Other Stockholders Equity depends on the Drug Manufacturers industry context. However, Other Stockholders Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Stockholders Equity mean?
A high Other Stockholders Equity can signal that a stock is expensive relative to its fundamentals. Other Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. View historical data on CSPC Pharmaceutical Group and its competitors. CSPC Pharmaceutical Group's current Other Stockholders Equity is $-301 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CSPC Pharmaceutical Group stock overvalued right now?
Based on GuruFocus' analysis, CSPC Pharmaceutical Group (CSPCY) is currently considered Modestly Overvalued. The stock's GF Value™ is $3.36, compared to a current price of $4.19 — trading 24.7% above its estimated fair value. The current Other Stockholders Equity is $-301 Mil. CSPC Pharmaceutical Group's overall GF Score™ is 74/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Stockholders Equity calculated?
Other Stockholders Equity is calculated from a company's financial statements. For CSPC Pharmaceutical Group (CSPCY), the current Other Stockholders Equity is $-301 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is CSPC Pharmaceutical Group (CSPCY) Overvalued in 2026?

Based on GuruFocus' analysis, CSPC Pharmaceutical Group stock appears to be overvalued. The current stock price of $4.19 is trading 24.7% above its estimated GF Value™ of $3.36. GuruFocus considers CSPC Pharmaceutical Group to be Modestly Overvalued.

Key valuation signals for CSPCY:

  • Other Stockholders Equity: $-301 Mil
  • GF Value™: $3.36 vs. price of $4.19 (24.7% above fair value)
  • GF Score™: 74/100 with 4 warning signs

No single metric tells the full story. See the CSPCY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

CSPC Pharmaceutical Group Business Description

Address No.896 Zhongshandong Street, Gaoxin District, Hebei Province, Shijiazhuang, CHN, 050035
CSPC Pharmaceutical Group LTD is engaged in the manufacture and sale of pharmaceutical products. The group's segments include: Finished drugs, consisting research and development, manufacture and sale of pharmaceutical products and license fee income; Bulk products, that manufacture and sale of vitamin C, and antibiotic products in bulk powder form; and Functional food and others, that manufacture and sale of functional food products (including caffeine food additives, anhydrous glucose, acarbose and vitamin C buccal tablets), provision of healthcare service and others. It derives maximum revenue from Finished Products segments. Geographically, the company operates in Chinese Mainland, which Chinese Mainland generates maximum revenue; Other Asian regions; Europe; North America; and Others.
74GF Score

Get the complete analysis for CSPCY

Other Stockholders Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$4.19
Price
$3.36
GF Value